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How did the study come about?
Childhood asthma resembles a complex syndrome
rather than a single disease. Clinical manifestations
include cough, shortness of breath and wheeze.1
Because of its high prevalence, it is of major public
health relevance.2,3 Presentation and disease course of
childhood wheezing disorders vary,4 and its pheno-
types are difficult to distinguish in early childhood
despite the demand for diverse therapeutic strategies.5
Current treatments have no sustained effect on devel-
opment of lung function and cannot prevent tracking
of reduced lung function.6
Risk factors for childhood wheeze and subsequent
asthma include genes, environmental factors and
their interaction:1,7,8 all these affect lung development
directly or indirectly (Figure 1). Data on the associ-
ation between lung development and respiratory
symptoms9 in early childhood are mostly derived
from small hospital-based studies. Larger epidemio-
logical studies have been based on questionnaires
and most studies have been conducted in older
children,2 in high-risk populations10 or retrospective-
ly.11 There is a lack of prospectively assessed lung
function studies in unselected healthy infants that
take into account genetic and environmental factors.
However, in order to disentangle the complex inter-
action of these predisposing factors on lung develop-
ment and childhood wheeze, relatively large groups of
infants need to be studied, with repeated lung func-
tion measurements, assessment of environmental and
hereditary factors and clinical outcomes. The ‘Bern
Infant Lung Development’ (BILD) cohort aims to con-
tribute towards closing this gap. It was set up in 1999
to study physiological properties of the respiratory
system and environmental and genetic risk factors af-
fecting lung development in healthy individuals from
infancy through childhood in relation to wheeze.9
How is it funded?
Direct costs of the cohort are being paid by project
grants from the Swiss National Science Foundation,
the European Respiratory Society (ERS), the Austrian,
German and Swiss Paediatric Respiratory Society
and Swiss Governmental Anti-Tobacco Fund. The
University Children’s Hospital in Bern, Switzerland,
where the study centre is located, provides the
infrastructure. All studies were approved by the local
Ethics Research Committee.
What does it cover?
In a comprehensive approach, we search for early
markers of common respiratory morbidity, including
respiratory infections and asthma, by trying to
disentangle predisposing and modifying factors of re-
spiratory morbidity within the context of lung devel-
opment. This includes the assessment of immune
development and markers of airway inflammation in
response to environmental triggers.
The strengths of the BILD cohort are its hallmarks:
the prospective approach with standardized data col-
lection starting before birth in unselected children;
the accurate and standardized measurements of lung
function and markers of airway inflammation; and
the detailed assessment of incidence and determin-
ants of respiratory symptoms especially during the
first year of life.12
To explain developing properties of lung and airways
during the vulnerable phases, lung function is mea-
sured at the age of 1 month and at the age of 6 years,
with further lung function measurements planned for
the age of 12 years.
We study the complex reaction of lung and airways
to environmental triggers, which is possibly
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influenced both by inflammation and immune re-
sponse. Here, we measure the association between
exposure to environmental tobacco smoke (ETS), air
pollution and lung function, markers of airway in-
flammation and components of the immune system.
In addition, we prospectively assess viral pathogens of
lower respiratory tract infections during the first year
of life, as well as related respiratory symptoms and
their severity.
Data covering genetic risk factors for childhood
asthma are rapidly increasing.13,14 However, little is
known about their effect on lung development and
childhood wheeze.14–16 This is particularly true for
genes known, from animal models, to be involved in
lung development. Therefore, we measure the effect
of single-nucleotide polymorphisms in these genes in
comparison with genes associated with clinical mani-
festation of childhood allergy, asthma or wheeze.
Who is in the sample?
Recruitment for the BILD cohort is ongoing; about
35 unselected healthy neonates enter the cohort
every year. Study participants are born after April
1999 in the agglomeration of Bern, the capital of
Switzerland. One-third of the study population
comes from the rural surroundings, and two-thirds
from the urban area of Bern, which still offers rela-
tively rural living conditions compared with other
European cities.
Pregnant mothers are recruited at the four major
maternity hospitals and practices of obstetricians in
the agglomeration of Bern through advertisements
and interviews. Interested families receive informative
letters describing involved measurements and are
contacted by the study centre. The following inclusion
criteria apply: White ethnicity, term delivery (at least
37 weeks), ability of parents to speak one of the
major Swiss languages (German, French), no severe
maternal health problems, no maternal drug abuse
other than nicotine, no known major birth defects
or perinatal disease of the newborn, such as respira-
tory distress, airway malformation or other major re-
spiratory diseases diagnosed after birth.
From 1999 until the end of 2009, a total of 42 110
mothers gave birth at the four major maternity hospitals
in the agglomeration of Bern. By the end of 2009, we
recruited 364 study participants (see Table 1 for an-
thropometric data of infants with lung function data),
and 107 have been followed-up so far at the age of 6 years
(Table 2). The others have not yet reached this age.
Figure 1 Proposed effect of environmental and genetic
risk factors and their interaction on lung development
and evolution of wheeze phenotypes. The Figure illustrates
how genetic background, environmental exposures (ETS,
air pollution, infections, allergens, active smoking) and their
interaction might influence lung growth and development
from branching of the airways to alveolarization. We
propose a direct effect of these exposures on lung develop-
ment, and an indirect effect via changes in the balance
between inflammation, injury and repair mechanisms,
leading to remodelling. Differences in these pathways
might lead to different phenotypes of wheezing disorders
Table 2 Number of participants initially recruited, number completing study Phases 1 and 2 and number of
drop-outs during study Phases 1 and 2 from 1999–2009 in the BILD cohort
Year 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
Total until
31/12/2009
Prenatally recruited 26 40 20 21 46 44 37 29 30 45 25 364
Completed study phase 1 23 37 19 20 45 44 36 28 29 44 25 350
Completed study phase 2 – – – – – – 28 14 11 18 36 107
Drop-outs during study phase 1 3 3 1 1 1 0 1 1 1 1 1 14
Drop-outs after study phase 1 – – – – – – 8 8 7 1 8 32
Table 1 Anthropometric data of study participants in the
BILD cohort with information on lung function (N¼ 344)
at the age of 1 month
Anthropometric data Median
Interquartile
range Range
Gestational age at birth
(weeks)
39.9 38.9–40.6 37.0–42.3
Birth weight (g) 3410 3060–3660 2170–4915
Age at study date (weeks) 5.0 4.6–5.4 3.6–8.3
Weight at study date (g) 4325 4010–4750 2890–6400
Length at study date (cm) 54.6 53.1–56.5 48.0–61.5
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How often have they been
followed-up? What is attrition
like?
The study design of the BILD cohort is shown in
Figure 2. It includes three study phases with three
questionnaires, weekly telephone interviews during
the first year of life, two visits to the study centre
and two visits to the families’ homes at the time of
the first lower respiratory infection.
Study Phase 1 starts with recruitment. After birth,
mid wives extract perinatal history from medical re-
cords, and take cord blood and first urine samples if
eligibility is confirmed. At the age of 1 month, the
infants visit the study centre. On this occasion, lung
function measurements and maternal skin-prick tests
are performed, and Questionnaire 1 is used to assess
pre- and perinatal history. During the first year of life,
study nurses perform regular weekly telephone calls
with standardized interviews.
After the first year of life, Study Phase 2 starts.
The first follow-up is performed at the age of
6 years, when participants visit the study centre
again to undergo lung function measurements and
skin-prick tests. Questionnaires 2 and 3 assess the
history during Study Phase 2. A further follow-up as
part of Study Phase 3, also including lung function
measurements and skin-prick tests, is planned for the
age of 12 years.
Attrition was low during Phase 1 and relatively low
during Phase 2. We lost only 13 of 364 recruited in-
fants (3.7%) during Phase 1 and only 31 of 138 chil-
dren (22.5%) during Phase 2 (Table 2). Drop-outs
were almost exclusively due to personal reasons (8
during Phase 1, 25 during Phase 2), and to families
moving away (1 during Phase 1, 5 during Phase 2).
Five children were excluded because of heart disease
diagnosed after the neonatal period (four in Phase 1
and one in Phase 2).
What has been measured?
The data are derived from four sources: (i) hospital
records; (ii) questionnaires; (iii) telephone interviews;
and (iv) objective measurements. A detailed descrip-
tion of data collected in the BILD cohort during
Phases 1 and 2 is given in Table 3.
Hospital records (i): these are used to extract infor-
mation about maternal warning signs during the
delivery and perinatal data.
Questionnaires (ii): these assess information
about health conditions, with an emphasis on respira-
tory and atopic symptoms, infections and socio-
demographic and environmental exposures. Question-
naire 1 also collects information on pre- and perinatal
risk factors including family and maternal past med-
ical history. Questionnaires 2 and 3 assess the study
participant’s history during Phase 2. While
Figure 2 The BILD cohort: time-flow of recorded data, as well as of tests and procedures performed during the follow-up.
Vt: tidal volume; FeNO: fraction of exhaled nitric oxide; MBW: multiple breath washout; FRC: functional residual
capacity; LCI: lung clearance index; PCR: polymerase chain reaction; Rint: airway resistance by interrupter; Reff: effective
airway resistance (measured by bodyplethysmography); FEV1: forced expiratory volume during the first second of
expiration; MEF25-75: midexpiratory flow
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Table 3 Detailed description of collected data and measurements in the BILD cohort during Phases 1 and 2
Data collection
from hospital
records,
questionnaires
and telephone
interviews
Study Phase 1
(pregnancy until age 1 year)
Study Phase 2
(age 1 year until age 6 years)
General health
condition
Source: hospital records
Maternal warning signs during delivery
Amount, quality of amniotic fluid,
aspiration of amniotic fluid, colour of
amniotic fluid (meconium)
Weight and quality of placenta
Premature rupture of membranes
Infection, antibiotics, chorioamnionitis
Perinatal warning signs
Apgar score
Apnoea, tachypnea, bradycardia, cyanosis,
expiratory groaning, signs of dyspnea,
bradycardia, abnormality cardiotocogram
pH measured in blood from umbilical vein
and artery, acidosis or alkalosis
Source: Questionnaires 2 and 3
Common colds, infections (especially upper
and lower respiratory tract, ear, nose,
throat), number and duration
Atopic rhinitis or conjunctivitis, seasonality
of symptoms, months of occurrence, effect
of symptoms on indoor and outdoor activ-
ities, hay fever
Asthma, severity; triggers, number and
severity of attacks; nocturnal/diurnal,
doctor-diagnosed asthma,
Atopic dermatitis
Behavioural problems, enuresis (primary,
secondary, diurnal, nocturnal)
Medication, paracetamol 12 months prior to
follow-up
Level and impairment of indoor and outdoor
activity, type of activity, indoor swimming
Medications 12 months prior to follow-up,
alternative medications and remedies used
Respiratory
symptoms
Source: weekly telephone interviews during first
year of life52,53
Source: Questionnaires 2 and 3
Respiratory symptoms (including cough and
wheeze during day and night, difficulty
breathing, feeding difficulties, reduced
activity)
Using standardized score to group symptoms
into four levels according to severity and
with high sensitivity for lower respiratory-
tract infections
Main outcome parameter: weeks with severe
respiratory symptoms (defined as total
number of weeks with day or night score
of 5353
Cough, type of cough, cough without
infection, triggers of cough, cough severity,
subjective assessment of first time of
cough, last time of cough, duration free of
cough during 12 months prior to follow-up,
seasonality of cough, months of occurrence
Audible wheeze, triggers of wheeze,
nocturnal, diurnal, subjective assessment of
first time of wheeze, last time of wheeze,
seasonality of wheeze, months of
occurrence
Rales or rhonchi, triggers of rales, rhonchi,
nocturnal, diurnal
Snoring, sleep disturbance, tonsillectomy
Environmental
exposures
Source: Questionnaire 1, weekly telephone
interviews during first year of life52,53
Source: Questionnaires 2 and 3
Pets and exact type of pet at home, during/
after pregnancy
Pets given away due to allergy/atopy in family
Farming exposure, animal type
Traffic exposure at home (trucks)
Type of heating, type of stove, chimney, open
fire place
Sleeping environment child (mattress,
encasement, sheepskin rug use)
Damage due to damp at home, assessment of
exposure to mould
Maternal active or passive smoking, ETS
exposure, number of cigarettes, smoking
cessation, coffee/tee and number of cups,
caffeine containing soft drinks, vitamin
supplement intake, fruit intake, antibiotics,
steroid treatment, respiratory infections,
gastrointestinal infections, urinary tract
Pets and exact type of pet at home
Pets given away due to allergy/atopy in family
Farming exposure, animal type
Traffic exposure at home (trucks)
Type of heating, type of stove, chimney,
open fire place
Living conditions (type of dwelling, rural/
urban, number of rooms, number of people
in household)
Diet (fruit, vegetables, sweets, chocolate,
fast food, snacks, unpasteurized milk)
Maternal active or passive smoking, ETS
exposure, number of cigarettes, smoking
cessation until first major follow-up at the
age of 6 years
Maternal and paternal active or passive
smoking, number of cigarettes, smoking
(continued)
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Table 3 Continued
Data collection
from hospital
records,
questionnaires
and telephone
interviews
Study Phase 1
(pregnancy until age 1 year)
Study Phase 2
(age 1 year until age 6 years)
infections, vaginitis, colpitis, worm
infections, other infections during
pregnancy and during first year of life
Paternal active smoking, number of
cigarettes, smoking cessation during
pregnancy and first year of life
cessation until first major follow-up at the
age of 6 years
Objective
measurements
Study Phase 1
(pregnancy until age 1 year)
Study Phase 2
(age 1 year until age 6 years)
Measurements
of lung
function and
inflammation
of airways
Tidal breathing measurements12,50
Unsedated infants, during quiet natural
sleep
Ultrasonic flowmeter (Spiroson,
EcoMedics AG, Duernten, Switzerland)
with infant face mask
Main outcome parameters: minute
ventilation (tidal volume multiplied by
respiratory rate) and expiratory flow
Measurement of fraction of exhaled nitric
oxide (FeNO)53
Rapid-response chemoluminescence
analyzer (CLD 88, EcoMedics AG,
Duernten, Switzerland), with a range of
0–100 parts per billion (ppb), infant face
mask
Breath-by-breath measurement
Main outcome parameter: mean FeNO
Multiple Breath Washouts
(Sulfurhexafluoride)32
Ultrasonic flowmeter (see above), infant
face mask
Main outcome parameters: lung volume
(FRC) and ventilation inhomogeneity (LCI)
Interrupter resistance measurement
Ultrasonic flowmeter (see above), shutter
box, infant face mask
Main outcome parameter: Rint
Anthropometric data at study date: body
weight and length, head circumference
Tidal breathing measurements
Quiet tidal breathing
Ultrasonic flowmeter (see left) with
mouth-piece, filter and nasal clamp
Main outcome parameters: minute
ventilation (tidal volume multiplied by
respiratory rate) and expiratory flow
Measurement of FeNO53
Rapid-response chemoluminescence
analyzer (CLD 88, EcoMedics AG,
Duernten, Switzerland), with a range
of 0–100 ppb
Breath-by-breath measurement and
single-breath manoeuvre, no nasal clamp
Main outcome parameter: mean FeNO
Multiple Breath Washouts (Helium)
Ultrasonic flowmeter (see above), nasal
clamp
Main outcome parameters: lung volume
(FRC) and ventilation inhomogeneity
(LCI)
Interrupter resistance measurement
Ultrasonic flowmeter (see above), nasal
clamp
Main outcome parameter: Rint
Spirometry (bodyplethysmography)
MasterScreen Body, Jaeger, Germany;
mouthpiece, filter, nasal clamp
Main outcome parameters: lung volume
(FRC, intrathoracic gas volume), forced
expiratory flows and volumes
Anthropometric data at study date: body
weight and length
Skin-prick test Maternal skin-prick test Child skin-prick test
Dog dander, cat dander, Dermatophagoides
pteronyssinus, mixed tree pollens, mixed
grass pollens, Alternaria tenuis, positive
control (histamine), negative control
(NaCl), Allergomed, Switzerland
Dog dander, Cat dander, Dermatophagoides
pteronyssinus, mixed tree pollens, mixed
grass pollens, Alternaria tenuis, positive
control (histamine), negative control
(NaCl), Allergomed, Switzerland
Immunology Specimen: cord blood
Haematocrite, haemoglobin count, white
blood cell count, leucocyte subtypes
Total IgE, eosinophil cationic protein,
eosinophil protein X, interleukin
subtypes, interferon subtypes
(continued)
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Table 3 Continued
Objective
measurements
Study Phase 1
(pregnancy until age 1 year)
Study Phase 2
(age 1 year until age 6 years)
Mannose-binding lectin (MBL) measured
as described previously with commer-
cially available ELISA kits
(Antibodyshop, Gentofte, Denmark)60
Microbiology Specimen: anterior nasal swabs
Taken at any first acute respiratory
infection, which is defined as 42 days
with cough or wheeze, together with
fever 4388C, acute rhinitis, otitis media
or pharyngitis; specimens are analysed by
polymerase chain reaction (PCR) based
assays, e.g. Taqman real-time PCR,
targeting 16 different respiratory viruses
commonly infecting humans54,60
Genetics deoxyribonucleic acid (DNA) extraction from
white blood cells from cord blood
DNA extraction from mucosa cells retrieved
per buccal swabs or from saliva collection
Analysis of single nucleotide polymorph-
isms (SNPs)
Analysis of copy number variants in genes
involved in lung growth per DNA chip
analysis
Analysis of SNPs and
Analysis of copy number variants in genes
involved in lung growth per DNA chip
analysis
ETS and caffeine Specimen: first urine after birth and urine
during first lower respiratory-tract infection
Nicotine and cotinine
Caffeine
Air pollution at
community level
Swiss National Air Pollution Monitoring
Network (Nationales Beobachtungsnetz fu¨r
Luftfremdstoffe, NABEL) measurement sites12
Daily mean levels of particulate matter with
aerodynamic diameter of <10 mm (PM10)
Daily mean levels of nitrogen dioxide (NO2)
Daily maximum of mean hourly levels of
ozone (O3)
Stationary passive samplers (Palmes Tubes)
at measurement sites: daily mean levels
of NO2
Swiss NABEL measurement sites12
Daily mean levels of PM10
Daily mean levels of NO2
Daily maximum of mean hourly levels
of O3
Stationary passive samplers (Palmes Tubes)
at measurement sites: daily mean levels
of NO2
Air pollution at
individual level
Mobile passive samplers: daily mean levels of
PM2.5 and PM10
Stationary passive samplers (Palmes Tubes)
at study participants’ homes: daily mean
levels of NO2
Mobile passive samplers: daily mean levels
of PM2.5 and PM10
Stationary passive samplers (Palmes Tubes)
at study participants’ homes: daily mean
levels of NO2
Extraction of
routine data Study Phases 1–2 (until age 6 years)
Sources:
Questionnaires
1–3, telephone
interviews
Study participant: name, gender, date of birth, maternity hospital, gestational age, birth weight,
birth length, multiple birth, birth order, vaccinations
Feeding (breastfed, gastroesophageal reflux, hypoallergenic supplement), supplementary
alimentation, later diet
Maternal and paternal hay fever, atopic dermatitis, asthma, therapy due to asthma or difficulty
breathing
Demographic and socio-economic information: mother and father: names, birth dates, occupa-
tion throughout study, nationality, religion, country of birth and language, all home addresses
from pregnancy throughout study
Families’ paediatrician name and address as well as of general practitioner, family history
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Questionnaire 1 contains validated questions from a
preschool cohort study,17,18 Questionnaires 2 and 3
include questions for school-age children from the
International Study of Asthma and Allergies in Child-
hood (ISAAC).19 All questionnaires have been vali-
dated and used, with little variation since 1999.
Questionnaire 1 is programmed as an online database
for data entry during interview, Questionnaires 2 and
3 are distributed to parents in paper form (see avail-
able as Supplementary Data at IJE online data A and
B available as Supplementary Data at IJE online).
Weekly telephone interviews (iii): these interviews
are carried out during the first year of life to collect
information about respiratory symptoms. This in-
cludes a standardized score with a high sensitivity
for lower respiratory-tract infections (Table 4).20
Changes in socio-demographic and environmental ex-
posures are also assessed (listed in Table 5 for the
study population with data from Phase 1). In the
event of a first lower respiratory-tract infection, the
study nurses visit the families twice within 3 weeks
and perform two anterior nasal swabs for virus diag-
nostics by polymerase chain reaction (PCR).
Objective measurements (iv): these measurements
during infancy include, besides the mentioned virus
diagnostics, a lung function test at the age of 1 month
in unsedated infants during quiet natural sleep (tidal
breathing measurements, multiple breath washouts,
interrupter resistance measurements). At the age of
6 years, the same lung function tests are performed,
supplemented by spirometry and bodyplethysmogra-
phy. The fraction of exhaled nitric oxide (FeNO), as
a marker of airway inflammation, is measured at both
time-points. All measurements are performed accord-
ing to current standards by the ERS and the American
Thoracic Society (ATS).21–24 Skin-prick tests are per-
formed in mothers during the first visit and in infants
at the age of 6 years.
In addition to data from questionnaires, ETS expos-
ure during pregnancy is objectively assessed by the
analysis of the first urine after birth. Exposure to out-
door air pollution on the community level is measured
by monitoring stations of the Swiss National Air
Pollution Network (NABEL), including daily mean
levels of particles with a 50% cut-off aerodynamic
diameter of 10 mm (PM10) and nitrogen dioxide
(NO2), as well as the daily maximum of mean
hourly levels of ozone (O3). Air pollution at the indi-
vidual level is measured in selected time periods
by mobile passive samplers (daily mean levels of
particles with a 50% cut-off aerodynamic diameter
of 2.5 mm (PM2.5) and PM10) and stationary passive
samplers at the measurement sites (daily mean levels
of NO2).
What has been found? Key
findings and publications
Development and standardization of
non-invasive lung function tests
To assess lung development in a large infant cohort,
one needs non-invasive tests that can be performed in
uncooperative study participants. In addition to the
standardized data collection, we have significantly
added to current ERS/ATS standards of lung function
measurements in infants23,24 and to the development
and standardization of additional non-invasive lung
function techniques.9,25–48
Early programmers of lung development
Since the beginning of our prospective birth cohort,
we have investigated physical properties of the air-
ways in infants prone to wheeze.9 We showed that
not only bronchoconstriction, but also impaired
airway growth, plays a role for the development of
wheeze.27,29 Even without current wheeze, infants
with a past history of wheeze display altered
airway wall mechanics. This might be due to
remodelling or independent developmental differences
already present at birth. This emphasizes the
importance of early programmers of lung
development.30,49,50
Outdoor air pollution might be such an early pro-
grammer. By modelling outdoor air pollution expos-
ure during pregnancy, we found that exposure to
PM10 was associated with altered lung function in
newborns and that NO2 levels were associated with
elevated FeNO levels after birth, indicating the induc-
tion of inflammatory response in infants. This was
enhanced if mothers smoked during pregnancy but
independent of maternal atopy.12 Although atopy is
a risk factor for allergic asthma, this adds to the
hypothesis that lung development and evolution of
Table 4 Symptom score used in weekly telephone interviews during the first year of life20
Symptom
score
Day-time symptoms (cough, wheeze or
breathing difficulties)
Night-time symptoms
(cough, wheeze or breathing difficulties)
0 None None
1 Slight; no treatment given Slight; sleep not disturbed
2 Required treatment but no help from outside Sleep disturbed once; no help required
3 Severe; required help from general practitioner (GP) Sleep disturbed more than once or child needed help
4 Very severe; admitted to hospital Sleep very disturbed or GP called
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allergic asthma might be partly independent
processes, which are both influenced by early
programmers.25,51
Prevalence, risk factors and prognosis of
respiratory symptoms in early life
We were among the first to present prospective data
on respiratory symptoms in a cohort of unselected
infants. The incidence of symptoms was increased in
infants of asthmatic mothers, whereas maternal hay
fever was inversely related to the number of symp-
toms.52 High FeNO levels after birth were associated
with severe symptoms during the first year of life in
the offspring of atopic mothers, which was again pro-
nounced if mothers smoked during pregnancy.53
Thus, FeNO after birth might be an important predict-
or of later respiratory symptoms and morbidity.
The role of viral triggers for early
respiratory-tract infections
We analysed the pattern of viral pathogens causing
respiratory infections during the first year of life
and found that rhinoviruses were most common, fol-
lowed by corona, parainfluenza and respiratory syn-
cytial viruses. Patterns differed also with regard to the
amount of viral shedding 3 weeks after incidence of
symptoms.54–56 Additionally, we showed that Human
Bocavirus (HBoV), a picornavirus isolated in children
with lower respiratory-tract infections from several
retrospective and hospital-based studies, is also asso-
ciated with respiratory disease in healthy Swiss in-
fants, and reported that HBoV circulates in an
endemic fashion in the community, thus confirming
the worldwide distribution.54
Early mechanisms and markers related to
airway inflammation, the development of
the immune system and childhood wheezing
disorders
We were able to add towards the knowledge about
the effects of environmental triggers on airway in-
flammation. We found that smoking during preg-
nancy has an effect on components of the innate
immune system of the offspring. Total leucocyte
counts in cord blood were significantly lower if
mothers smoked during pregnancy. The decrease
was most prominent in neutrophils, monocytes, den-
dritic cells and lymphocytes.57 Investigating the
impact of outdoor air pollution on cytokine levels
as of monocyte chemotactic protein-1 (MCP-1),
interleukin-6 (IL-6), IL-10, for which large changes
are seen after exposure to high pollution levels such
as after bushfires, we found only small effects in cord
blood of healthy term infants.58,59
Assessing the quantitative effect of the acute-phase
plasma collection mannose-binding lectin (MBL) on
respiratory morbidity, we found that low levels were
only weakly associated, and high levels more strongly
associated, with the incidence and severity of
respiratory symptoms during the first year of life,
particularly in infants with asthmatic parents.60
What are the main strengths
and weaknesses?
The BILD cohort, with its unique data set of com-
prehensive lung function data, particularly during
Table 5 Risk factors for respiratory disease of infants
during Phase 1 of the BILD cohort
Number
of
infants
Proportion
of infants
(%)
History of maternal asthma
Negative 320 88.6
Positive 39 10.8
Unknown 2 0.6
History of paternal asthma
Negative 323 89.0
Positive 36 9.9
Unknown 4 1.1
History of maternal atopic diseasea
Negative 233 64.2
Positive 126 34.7
Unknown 4 1.1
Skin-pick test results in mothersb
Negative 197 65.0
Positive 106 35.0
Maternal smoking during pregnancy
Negative 316 87.5
Positive 42 11.6
Unknown 3 0.8
Paternal smoking during pregnancy
Negative 280 77.1
Positive 76 20.9
Unknown 7 1.9
Older siblings
None 181 50.1
One 114 31.6
More than one 58 16.1
Unknown 8 2.2
This Table shows the distribution of risk factors for respiratory
disease of study participants during Phase 1 of the BILD cohort,
i.e. during the first year of life (n¼ 364, information could not
be retrieved for 3 out of 14 drop-outs during Phase 1).
aEither maternal history of allergic rhinitis, allergic asthma or
atopic dermatitis.
bSkin-prick tests were performed in a subgroup of 303 mothers.
Tests were positive in case of hives bigger than positive control
(histamine) in any of the tested common allergens.
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infancy, is an integrative and interdisciplinary frame-
work to analyse how predisposing factors affect lung
development from pregnancy through childhood and
to predict later risk of respiratory disease. Especially
with regard to the costly and time-consuming lung
function measurements in infants, the BILD cohort
has a number of methodological strengths, and
normative data collected during these measurements
in the BILD cohort have been published meanwhile.61
To ensure comparability, we measure lung function at
any age in a standardized way, using the same tech-
nique and equipment on every subsequent occasion
in the same order. Measurements are performed
according to the latest recommendations by the ERS
and ATS; often we were even stricter. For instance,
for the analysis of tidal breathing at the age of
1 month, we used 100 instead of 30 breaths as
currently recommended, for better accuracy.21 There
is still enough flexibility to develop new lung function
testing methods.32,36 To validate exposure to air pol-
lutants, we have started to assess individual exposure
to air pollutants using passive samplers, which is
expensive and has yet been rarely used in studies
assessing the effect of long-term exposure to air
pollution on lung function.
The BILD cohort has a prospective design. It in-
cludes data assessments before and after birth, close
follow-up with weekly standardized telephonic inter-
views until the age of 1 year and a detailed reassess-
ment at the age of 6 years. Lung function tests are
performed at several time points covering the vulner-
able phases of lung development (growth of airways
and alveoli) during gestation and childhood. This fa-
cilitates disentangling effects of pre- and perinatal
risk factors from those of post-natal risk factors,
such as exposure to airway pollutants.
With all included infants being healthy and of a
narrow age range and all measurements in infants
performed during quiet natural sleep, comparability
within the cohort is given. Confounders such as
physical activity, obesity and hypoxia important for
older children are negligible in the studied infants.
Nevertheless, these influences are prospectively
assessed and will be included in the analysis of meas-
urements at school age.
We have only minimal attrition during the study,
especially during Phase 1, comparing favourably
with other studies.62 This is probably due to the
regular follow-up, particularly the weekly telephone
interviews during the first year of life. The draw-
back of such a detailed time-consuming study is
that it can only be done on a limited number of
participants.
Selection bias is not a major issue, as all participants
are recruited prenatally without knowledge of expos-
ures and outcomes. These are assessed and analysed
independently from each other. So far, we have been
able to adjust for known biological, time-variant and
further possible confounders.
All involved families were recruited in maternity
hospitals and only a minority of children born
during the study period in the region was recruited.
Although the main reason for non-participation was
lacking information about the study, participants
are likely to be biased towards a well-educated
middle-class population. This is the case with most
studies involving detailed measurements. In our ana-
lyses, social class has so far neither been a risk factor
nor a risk modifier for outcome measures. Therefore,
although we believe that most results are fairly rep-
resentative for the general population, it must be
kept in mind that not all findings can be extrapolated
to all Swiss or European children. Replication of the
findings in independent cohorts is desirable.
Can I get hold of the data?
Where can I find out more?
The Bern cohort studies are carried out at the
Department of Paediatric Pulmonology at Children’s
University Hospital Bern, Switzerland. The depart-
ment’s homepage provides information regarding
personal contact data, team members and publica-
tions (http://www.kinderkliniken.insel.ch/kiheil-pneu-
mologie.html). The principal investigator is Prof.
Dr Urs Frey, MD PhD, head of the University
Children’s Hospital (UKBB), Basel, Switzerland.
Researchers interested in collaborative work or further
information are invited to contact the principal inves-
tigator, Urs Frey, urs.frey@ukbb.ch.
Supplementary Data
Supplementary Data are available at IJE online.
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